Tender Details
Beyond this tender, use our platform to source any product, service, or solution.
Get direct quotes or register as a qualified provider.
About Tender
π Invitation For Bid: Ranibizumab Injection Vial ππ The Ministry Of Railways, Under The Central Government, Invites Bids For A Running Contract To Supply Inj. Ranibizumab (10mg/Ml) Vials. π₯ The Medicine Is Indicated For Various Ocular Conditions Including Wet Age Related Macular Degeneration (Amrd), Diabetic Macular Oedema (Dmo), Retinal Vein Occlusion (Rvo), Myopic Choroidal Neovascularization (Cnvm), Proliferative Diabetic Retinopathy (Pdr), And Retinopathy Of Prematurity (Rop). ποΈ π Bid Submission Deadline: June 20, 2024, 2:00 Pm A Bid Security Of Inr 5,43,50 Is Required. Interested Pharmaceutical Companies Must Ensure Their Bids Comply With The Drug Controller General Of India (Dcgi) Approval And Other Tender Specifications. Keywords: Ranibizumab, Injection, Vial, Dcgi Approved, Ocular Diseases, Ministry Of Railways, Government Tender, Pharmaceutical Supplies| Particulars | Details |
|---|---|
| Title |
Running Contract For Inj. Ranibizumab (10mg/Ml)) (0.23mg/0.23ml) For Intravitreal Injection Vial, The Medicine Should Be Approved By Dcgi For Wet Armd, Diabetic Macular Oedema, Rvo, Myopic Cnvm, Pdr And Rop.
|
| Description |
For Complete Deion And Other Details, Please Refer To Tender
|
| Organisation | Ministry of Railways | Central Govt. Ministry/Department |
| Tender Id | 106357554 |
|
Reference Number |
HB246126 |
| Tender Fee | 0 |
| EMD | 54350 |
| Tender Value | - |
| Place | Kolkata |
| Link |
View Original Tender Notice
https://www.ireps.gov.in/ireps/supply/pdfdocs/062024/106357554/viewNitPdf_4584480.pdf |
| Start Date | May 27, 2024 18:14 |
| End Date |
Expired
20/06/2024
Expired 819 days ago |
Tender Support
Get help with filing, GeM registration, documents, or relevant tender alerts.
Running contract for inj. ranibizumab (10 mg/ml) (0.23 mg/0.23 ml)for intravitreal injection vial. the medicine should be approved by dcgi for wet armd, diabetic macular oedema, rvo, myopic cnvm, pdr and rop.
For complete deion and other details, please refer to tender
Read moreRanibizumab 2.3mg inj approved by cdsco for the following indications- 1) wet amd, 2) diabetic macular edema, 3) retinal vein occlusion, 4) myopic cnvm, 5) proliferative diabetic retinopathy
For complete deion and other details, please refer to tender
Read moreInj. ranibizumab (each pfs/ amp/vial contains ranibizumab upto 2.3 mg/ 0.23 ml) {the drug should be dgci approved for diabetic macular oedema, retinal vein occlusion, proliferative diabetic retinopathy, retinopathy of prematurity and myopic choroidal neovascular membrane.}
For complete deion and other details, please refer to tender
Read moreInj. ranibizumabo.23ml, 10mg/ml vial, ra [inj. ranibizumabo.23ml, 10mg/ml vial, ranibizumab biosimilar, the medicine should be approved by dcgi/fda for wet amd, diabetic macular edema, rv0, myopic cnvm ,retinopathy of prematurity and pdr .]
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - pfs approved for all indications 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreof your Industry type